<DOC>
	<DOCNO>NCT02064049</DOCNO>
	<brief_summary>The purpose study ass feasible treat prevent transmission Hepatitis C prison set achieve substantial reduction incidence prevalence Hepatitis C. It hypothesise rapid scale-up Hepatitis C Virus ( HCV ) treatment interferon-free Direct Acting Anti-virals ( DAAs ) prison inmate achieve &gt; 50 % reduction incidence HCV infection two year period prison setting .</brief_summary>
	<brief_title>Surveillance Treatment Prisoners With Hepatitis C</brief_title>
	<detailed_description>The study conduct initially two maximum security prison locate New South Wales , Australia comprise four phase : Phase 1 , Surveillance HCV Incidence Prevalence Liver Disease Burden : The HCV incidence prevalence phase prospective longitudinal cohort . HCV incidence prevalence liver disease burden monitor regular six-monthly cross-sectional survey participant 3.5 year . Phase 2 , Modelling : The data year 1 surveillance HCV incidence prevalence phase use model number participant require treated demonstrate 50 % reduction incidence . Phase 3 , Treatment Intervention : The treatment intervention conduct one maximum security prison ( Treatment Prison ) . The second prison continue care HCV infect inmate per standard care ( Control Prison ) . The intervention component study consist phase IV open-label study interferon-free DAAs treatment HCV infection . The treatment phase commence year 2 two year duration . The exact drug combination regimen use treatment intervention determine year 1 phase II III data sofosbuvir ledipasvir potential interferon-free DAA regimen publish . The exact number participant require demonstrate 50 % reduction incidence determine model phase . Phase 4 , Cost-effectiveness : During treatment intervention phase participant require complete survey obtain estimate health outcome ( EQ-5D survey ) regular interval . This data use health economist determine cost effectiveness treatment prevention prison setting .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Surveillance HCV Incidence Prevalence Inclusion criteria 1 . 18 year age old 2 . Voluntarily sign ( surveillance phase ) inform consent form . 3 . Adequate English mental health status provide write informed consent comply study procedure Exclusion criterion 1 ) Prisoners security classification make clinic attendance study visit logistically difficult 5.2 Treatment Intervention Inclusion criteria 1 . 18 year age old . 2 . Voluntarily sign ( treatment phase ) inform consent form . 3 . Detectable HCV RNA plasma . 4 . HCV genotypes 16 5 . Anticipated incarceration duration &gt; 12 week follow planned commencement therapy . 6 . Compensated liver disease follow criterion must meet : 1 . INR &lt; 1.8 2 . Albumin &gt; 30 g/L 3 . Bilirubin &lt; 35umol/L 7 . Prisoners Fibroscan &gt; 12KPa AFP &gt; 50 ng/mL must abdominal ultrasound CT scan without evidence hepatocellular carcinoma within 2 month prior screen . 8 . Negative pregnancy test baseline ( female childbearing potential ) . 9 . [ For prisoner release treatment followup ] If engage sexual intercourse may potentially result pregnancy , fertile male must use effective contraception treatment 90 day treatment end , fertile female must use effective contraception treatment 30 day treatment end 10 . If coinfection HIV document , subject must meet following criterion : 1 . Antiretroviral ( ARV ) untreated &gt; 8 week precede screen visit CD4 T cell count &gt; 500 cells/mm3 OR 2 . On stable ARV regimen &gt; 8 week prior screen visit , CD4 T cell count &gt; 200 cells/mm3 undetectable plasma HIV RNA level . Suitable ARV include : Nucleos ( ) ide reverse transcriptase inhibitor : Tenofovir disoproxil fumarate ( TDF ) , tenofovir alafenamide ( TAF ) , emtricitabine ( FTC ) Nonnucleoside reverse transcriptase inhibitor : Rilpivirine Protease inhibitor : Atazanavir , darunavir , lopinavir , ritonavir Integrase inhibitor : Dolutegravir , raltegravir , elvitegravir/cobicistat Contraindicated ARV include : Efavirenz ( 50 % reduction velpatasvir exposure ) Didanosine Zidovudine Tipranavir Other ARV agent may permissible time study commencement pending drugdrug interaction study ; please discuss Medical Monitor . Exclusion criteria 1 . Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; 6 month prior first dose study drug . 2 . Any investigational drug &lt; 6 week prior first dose study drug . 3 . History evidence clinical hepatic decompensation ( i.e . ascites , encephalopathy oesophageal variceal haemorrhage ) 4 . Solid organ transplant 5 . Clinically significant illness ( HCV ) major medical disorder may interfere prisoner treatment , assessment compliance protocol ; prisoner currently evaluation potentially clinically significant illness ( HCV ) also exclude . 6 . History follow : 1 . Malignancy within 5 year prior screen , exception specific cancer may cure surgical resection ( basal cell skin cancer , etc. ) . Subjects evaluation possible malignancy also exclude . 2 . Significant drug allergy ( anaphylaxis hepatotoxicity ) . 7 . Any following lab parameter screen : 1 . ALT &gt; 10 x ULN 2 . AST &gt; 10 x ULN 3 . Direct bilirubin &gt; 1.5 x ULN 4 . Platelets &lt; 50,000/uL 5 . Creatinine clearance &lt; 60 mL/min 6 . Haemoglobin &lt; 11 g/dL female ; &lt; 12 g/dL male 7 . Albumin &lt; 30g/L 8 . INR &gt; 1.5 ULN unless subject know haemophilia stable anticoagulant regimen affect INR 8 . Chronic use systemically administer immunosuppressive agent ( e.g . prednisone equivalent &gt; 10 mg/day ) 9 . Known hypersensitivity VEL , SOF formulation excipients . 10 . Use prohibit concomitant medication describe section 6.2 11 . Pregnant nursing female 12 . Ongoing severe psychiatric disease judge treat physician . 13 . Frequent inject drug use judge treat physician compromise treatment safety . 14 . Inability unwillingness provide inform consent abide requirement study . 15 . Any criterion judge treat physician potentially compromise treatment safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>People inject drug</keyword>
	<keyword>Drug user</keyword>
	<keyword>Direct act antiviral ( DAA )</keyword>
	<keyword>Infectious disease</keyword>
	<keyword>Prisoners</keyword>
</DOC>